Novavax Reports Full Product Registration In South Africa Of Novavax COVID-19 Vaccine

Novavax, Inc. (NVAX) and Serum Institute of India Pvt. Ltd. announced that the South African Health Products Regulatory Authority has granted full product registration with conditions for Novavax' protein-based vaccine, NVX-CoV2373, as a two-dose primary series for active immunization to prevent COVID-19 in adults aged 18 and older. The Novavax vaccine is marketed in South Africa under the brand name Covovax.

NVX-CoV2373 has received authorization for use in adults aged 18 and older from more than 43 countries, including the U.S., and from the WHO.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Follow RTT